Second-line interventions for migraine in the emergency department: A narrative review
CONCLUSIONS: There are no evidence-based second-line treatments of migraine in the ED setting. For patients with migraine, who fail to improve after treatment with a first-line medication, it is reasonable to use an intravenous NSAID or intravenous acetaminophen. Alternatively, clinicians adept at performing a GONB may offer this treatment.PMID:34806767 | DOI:10.1111/head.14239 (Source: Headache)
Source: Headache - November 22, 2021 Category: Neurology Authors: Farnam Kazi Mallika Manyapu Maha Fakherddine Kumelachew Mekuria Benjamin W Friedman Source Type: research
Second-line interventions for migraine in the emergency department: A narrative review
CONCLUSIONS: There are no evidence-based second-line treatments of migraine in the ED setting. For patients with migraine, who fail to improve after treatment with a first-line medication, it is reasonable to use an intravenous NSAID or intravenous acetaminophen. Alternatively, clinicians adept at performing a GONB may offer this treatment.PMID:34806767 | DOI:10.1111/head.14239 (Source: Headache)
Source: Headache - November 22, 2021 Category: Neurology Authors: Farnam Kazi Mallika Manyapu Maha Fakherddine Kumelachew Mekuria Benjamin W Friedman Source Type: research
Second-line interventions for migraine in the emergency department: A narrative review
CONCLUSIONS: There are no evidence-based second-line treatments of migraine in the ED setting. For patients with migraine, who fail to improve after treatment with a first-line medication, it is reasonable to use an intravenous NSAID or intravenous acetaminophen. Alternatively, clinicians adept at performing a GONB may offer this treatment.PMID:34806767 | DOI:10.1111/head.14239 (Source: Headache)
Source: Headache - November 22, 2021 Category: Neurology Authors: Farnam Kazi Mallika Manyapu Maha Fakherddine Kumelachew Mekuria Benjamin W Friedman Source Type: research
Second-line interventions for migraine in the emergency department: A narrative review
CONCLUSIONS: There are no evidence-based second-line treatments of migraine in the ED setting. For patients with migraine, who fail to improve after treatment with a first-line medication, it is reasonable to use an intravenous NSAID or intravenous acetaminophen. Alternatively, clinicians adept at performing a GONB may offer this treatment.PMID:34806767 | DOI:10.1111/head.14239 (Source: Headache)
Source: Headache - November 22, 2021 Category: Neurology Authors: Farnam Kazi Mallika Manyapu Maha Fakherddine Kumelachew Mekuria Benjamin W Friedman Source Type: research
Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks
Arch Biochem Biophys. 2021 Nov 17:109085. doi: 10.1016/j.abb.2021.109085. Online ahead of print.ABSTRACTThe identification of biomolecules associated with papillary thyroid cancer (PTC) has upmost importance for the elucidation of the disease mechanism and the development of effective diagnostic and treatment strategies. Despite particular findings in this regard, a holistic analysis encompassing molecular data from different biological levels has been lacking. In the present study, a meta-analysis of four transcriptome datasets was performed to identify gene expression signatures in PTC, and reporter molecules were determ...
Source: Archives of Biochemistry and Biophysics - November 20, 2021 Category: Biochemistry Authors: Gizem Gulfidan Melisa Soylu Damla Demirel Habib Burak Can Erdonmez Hande Beklen Pemra Ozbek Sarica Kazim Yalcin Arga Beste Turanli Source Type: research
Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks
Arch Biochem Biophys. 2021 Nov 17:109085. doi: 10.1016/j.abb.2021.109085. Online ahead of print.ABSTRACTThe identification of biomolecules associated with papillary thyroid cancer (PTC) has upmost importance for the elucidation of the disease mechanism and the development of effective diagnostic and treatment strategies. Despite particular findings in this regard, a holistic analysis encompassing molecular data from different biological levels has been lacking. In the present study, a meta-analysis of four transcriptome datasets was performed to identify gene expression signatures in PTC, and reporter molecules were determ...
Source: Archives of Biochemistry and Biophysics - November 20, 2021 Category: Biochemistry Authors: Gizem Gulfidan Melisa Soylu Damla Demirel Habib Burak Can Erdonmez Hande Beklen Pemra Ozbek Sarica Kazim Yalcin Arga Beste Turanli Source Type: research
Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation
Free Radic Biol Med. 2021 Nov 3:S0891-5849(21)00788-7. doi: 10.1016/j.freeradbiomed.2021.11.001. Online ahead of print.ABSTRACTLung cancer is considered as leading cancer with the highest mortality. The KRAS-oncogenic mutations are dominant in lung carcinoma leading to poor prognosis and radioresistance, which is a major impediment to radiotherapy. Thus, KRAS mutant inhibitors that synergistically sensitize tumours to radiation are urgently needed. In pursuance of the search for a novel radiosensitizer, high-throughput screening of FDA-approved drugs was performed at active site of K-Ras. Prochlorperazine (PCZ), an antipsy...
Source: Mol Biol Cell - November 7, 2021 Category: Molecular Biology Authors: Kirti Sad Palak Parashar Pragya Tripathi Hungharla Hungyo Ramesh Sistla Ravi Soni Vibha Tandon Source Type: research
Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation
Free Radic Biol Med. 2021 Nov 3:S0891-5849(21)00788-7. doi: 10.1016/j.freeradbiomed.2021.11.001. Online ahead of print.ABSTRACTLung cancer is considered as leading cancer with the highest mortality. The KRAS-oncogenic mutations are dominant in lung carcinoma leading to poor prognosis and radioresistance, which is a major impediment to radiotherapy. Thus, KRAS mutant inhibitors that synergistically sensitize tumours to radiation are urgently needed. In pursuance of the search for a novel radiosensitizer, high-throughput screening of FDA-approved drugs was performed at active site of K-Ras. Prochlorperazine (PCZ), an antipsy...
Source: Free Radical Biology and Medicine - November 7, 2021 Category: Biology Authors: Kirti Sad Palak Parashar Pragya Tripathi Hungharla Hungyo Ramesh Sistla Ravi Soni Vibha Tandon Source Type: research
Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation
Free Radic Biol Med. 2021 Nov 3:S0891-5849(21)00788-7. doi: 10.1016/j.freeradbiomed.2021.11.001. Online ahead of print.ABSTRACTLung cancer is considered as leading cancer with the highest mortality. The KRAS-oncogenic mutations are dominant in lung carcinoma leading to poor prognosis and radioresistance, which is a major impediment to radiotherapy. Thus, KRAS mutant inhibitors that synergistically sensitize tumours to radiation are urgently needed. In pursuance of the search for a novel radiosensitizer, high-throughput screening of FDA-approved drugs was performed at active site of K-Ras. Prochlorperazine (PCZ), an antipsy...
Source: Molecular Medicine - November 7, 2021 Category: Molecular Biology Authors: Kirti Sad Palak Parashar Pragya Tripathi Hungharla Hungyo Ramesh Sistla Ravi Soni Vibha Tandon Source Type: research
Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation
Free Radic Biol Med. 2021 Nov 3:S0891-5849(21)00788-7. doi: 10.1016/j.freeradbiomed.2021.11.001. Online ahead of print.ABSTRACTLung cancer is considered as leading cancer with the highest mortality. The KRAS-oncogenic mutations are dominant in lung carcinoma leading to poor prognosis and radioresistance, which is a major impediment to radiotherapy. Thus, KRAS mutant inhibitors that synergistically sensitize tumours to radiation are urgently needed. In pursuance of the search for a novel radiosensitizer, high-throughput screening of FDA-approved drugs was performed at active site of K-Ras. Prochlorperazine (PCZ), an antipsy...
Source: Mol Biol Cell - November 7, 2021 Category: Molecular Biology Authors: Kirti Sad Palak Parashar Pragya Tripathi Hungharla Hungyo Ramesh Sistla Ravi Soni Vibha Tandon Source Type: research
Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation
Free Radic Biol Med. 2021 Nov 3:S0891-5849(21)00788-7. doi: 10.1016/j.freeradbiomed.2021.11.001. Online ahead of print.ABSTRACTLung cancer is considered as leading cancer with the highest mortality. The KRAS-oncogenic mutations are dominant in lung carcinoma leading to poor prognosis and radioresistance, which is a major impediment to radiotherapy. Thus, KRAS mutant inhibitors that synergistically sensitize tumours to radiation are urgently needed. In pursuance of the search for a novel radiosensitizer, high-throughput screening of FDA-approved drugs was performed at active site of K-Ras. Prochlorperazine (PCZ), an antipsy...
Source: Free Radical Biology and Medicine - November 7, 2021 Category: Biology Authors: Kirti Sad Palak Parashar Pragya Tripathi Hungharla Hungyo Ramesh Sistla Ravi Soni Vibha Tandon Source Type: research
Prescription Pattern and Off-Label Use of Antipsychotics in a Middle Eastern Population
Conclusion: Non-mental health and off-label prescriptions of several antipsychotics were observed. Integration of this data with pharmacogenomic and clinical outcome data will help in determining the course of action for implementing personalized and precision medicine in the country and beyond. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - November 1, 2021 Category: Drugs & Pharmacology Source Type: research
Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report
ConclusionsThe metabolism of ondansetron, metoclopramide, or prochlorperazine in patients with the *41CYP2D6 allele has not been studied. In this family, clinical evidence implicates the *41CYP2D6 allele as causing extrapyramidal adverse pharmacologic reactions. Patients with a family history of medication-induced dystonia involving these medications should be considered for pharmacogenomic testing, and patients carrying the *41CYP2D6 allele should consider reduction or avoidance of CYP2D6-mediated medications to minimize the potential risk of adverse extrapyramidal effects. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - August 19, 2021 Category: General Medicine Source Type: research
A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis
CONCLUSIONS: Prochlorperazine plus diphenhydramine is more efficacious than hydromorphone for the treatment of migraine-associated symptoms.PMID:34363617 | DOI:10.1111/head.14185 (Source: Headache)
Source: Headache - August 7, 2021 Category: Neurology Authors: Fred Cohen Benjamin W Friedman Source Type: research
A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis
CONCLUSIONS: Prochlorperazine plus diphenhydramine is more efficacious than hydromorphone for the treatment of migraine-associated symptoms.PMID:34363617 | DOI:10.1111/head.14185 (Source: Headache)
Source: Headache - August 7, 2021 Category: Neurology Authors: Fred Cohen Benjamin W Friedman Source Type: research
